Envista Holdings Corp
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Healthcare stocks have outperformed the S&P 500, but some companies face challenges. Bausch + Lomb (BLCO) has declining EPS and free cash flow margins. Envista (NVST) shows weak sales growth and profitability. Progyny (PGNY) struggles with unit sales and capital returns. All three trade at forward P/E ratios of 16.9x, 17.5x, and 11.8x respectively.
Envista Holdings Corp (NVST) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 8.01 of this Current Report on Form 8-K, disclosing the Company’s Board of Directors’ appointment of Paul Keel, the Company’s President and Chief Executive Officer, to the role of Chairman of the Board, effective immediately. On August 17, 2026, the Compensation Committee of
Envista (NVST) reported Q2 2026 results on an earnings call, citing 5% core growth and sales of $731 million. Adjusted gross margin rose to 55.1%, adjusted EBITDA grew 28% with 14.7% margin, and adjusted EPS was $0.41 (+58%). Free cash flow was $105 million. The company raised 2026 guidance: core growth 3.5% to 4.5%, adjusted EBITDA 11% to 14%, adjusted EPS $1.50 to $1.55.
Over the past 7 days, alphai's AI scored 1 news story mentioning NVST (Envista Holdings Corp). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent NVST coverage spans financial news, earnings and corporate actions.
In the last 30 days, NVST insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($220K). The most active reporter was Reis Mischa, SVP, Strategy & Bus. Dev., with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Weak growth and declining earnings raise concerns, could limit upside.
The compensation boost signals strong board confidence in management, likely supporting short‑term price appreciation.
Guidance raise plus strong Q2 margin, EPS, and free cash flow conversion likely supports upward estimate revisions and near-term momentum.
Multiple Buy ratings with targets above the prior close support constructive sentiment, but the news is not a fresh fundamental development.
Beat on revenue and adjusted EPS, plus raised FY EPS, supports near-term upside bias but guidance deceleration tempers follow-through.
alphai scores every news story that mentions NVST with an AI model for sentiment and relevance, and aggregates insider trades from Envista Holdings Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Healthcare stocks have outperformed the S&P 500, but some companies face challenges. Bausch + Lomb (BLCO) has declining EPS and free cash flow margins. Envista (NVST) shows weak sales growth and profitability. Progyny (PGNY) struggles with unit sales and capital returns. All three trade at forward P/E ratios of 16.9x, 17.5x, and 11.8x respectively.
3 min readEnvista Holdings Corp (NVST) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 8.01 of this Current Report on Form 8-K, disclosing the Company’s Board of Directors’ appointment of Paul Keel, the Company’s President and Chief Executive Officer, to the role of Chairman of the Board, effective immediately. On August 17, 2026, the Compensation Committee of
2 min readEnvista (NVST) reported Q2 2026 results on an earnings call, citing 5% core growth and sales of $731 million. Adjusted gross margin rose to 55.1%, adjusted EBITDA grew 28% with 14.7% margin, and adjusted EPS was $0.41 (+58%). Free cash flow was $105 million. The company raised 2026 guidance: core growth 3.5% to 4.5%, adjusted EBITDA 11% to 14%, adjusted EPS $1.50 to $1.55.
12 min readAnalysts at Barclays and others updated views on healthcare stocks. Protagonist Therapeutics (PTGX): Barclays reiterated Buy, $153 target; TipRanks consensus Strong Buy, $133 average; TipRanks upgraded to Buy with $151 target. Qiagen (QGEN): Barclays Hold, $38 target; consensus Moderate Buy, $42.48. Envista Holdings (NVST): Barclays Buy, $32 target; consensus Moderate Buy, $30; BofA Buy, $34.
3 min readEnvista Holdings (NYSE: NVST) reported Q2 CY2026 revenue of $730.5 million, up 7.1% year on year and about 2% above Wall Street estimates. Non-GAAP EPS was $0.41, up from $0.26 a year earlier, and 22.1% above consensus. Analysts expect next 12 months revenue growth of 1.1% and FY EPS around $1.47.
4 min readEnvista Holdings Corp (NVST) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Envista Reports Second Quarter 2026 Results BREA, Calif., August 5, 2026 / PRNewswire / -- Envista Holdings Corporation (NYSE: NVST) today announced results for the quarter ended July 3, 2026. “We built on our fast start in Q1 with continued good performance in Q2,”
6 min readEnvista Holdings (NYSE: NVST) will report earnings Wednesday after market hours. The company last quarter posted revenue of $705.5 million, up 14.4% year on year, and beat EPS and revenue expectations. For the upcoming quarter, analysts expect about 5% revenue growth. NVST trades near $27.37 with an average analyst price target of $29.43.
2 min readA Business Journal list of Orange County dental companies says PDS Health (formerly Pacific Dental Services) became the No. 1 dental firm by employee count, with 1,381 workers, up 6.8%. OC headcount fell 2% to 5,126. Envista drove much of the decline, while Envista reported 12-month revenue up 8% to $2.7B and shares up about 36% to above $28.
7 min readAriel Investments highlighted Envista Holdings (NYSE:NVST). Barclays reiterated an Overweight rating but cut its price target to $32 from $34. The article cites Envista’s Q1 results: 9.5% core revenue growth, 25% adjusted EBITDA growth, and 50% EPS growth, with full-year guidance for sales +2% to +4%, adjusted EBITDA +7% to +13%, and EPS $1.35–$1.45.
4 min readVanguard Capital Management has disclosed an 8,574,557-share stake in Envista Holdings Corp (NVST), representing 5.23% of the company's common stock as of March 31, 2026. This Schedule 13G filing indicates Vanguard holds sole dispositive power over all these shares and sole voting power over 1,255,976 shares. The investment is described as being in the ordinary course of business and not for the purpose of influencing control of the issuer.
2 min read
